Compounds > 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone
Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Aortic Diseases

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Aortic Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnesen, H; Falk, E; Kontny, F; Kwong, E; Lyngdorf, L; Meztli, A; Olesen, M; Seljeflot, I1

Other Studies

1 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Aortic Diseases

ArticleYear
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.
    Scandinavian cardiovascular journal : SCJ, 2002, Volume: 36, Issue:6

    Topics: Algorithms; Analysis of Variance; Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase Inhibitors; Disease Models, Animal; Furans; Male; Mice; Mice, Inbred C57BL; Sulindac

2002